search
Back to results

Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants (PAS)

Primary Purpose

Low Birth Weight

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)
Placebo
Sponsored by
Vermont Oxford Network
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Low Birth Weight focused on measuring extremely low birth weight, probiotics, growth, nutrition, premature infants, growth in extremely low birth weight infants

Eligibility Criteria

1 Day - 14 Days (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • birth weight less than or equal to 1000 grams,
  • appropriately grown for gestational age,
  • age 1 to 14 days inclusive,
  • intention to start enteral feeds,
  • written informed consent obtained

Exclusion Criteria:

  • known life-threatening congenital anomaly or condition affecting
  • gastrointestinal function,
  • previous NEC or gastrointestinal perforation,
  • previous supplementation with probiotics
  • previous enteral feedings

Sites / Locations

  • St. John Hospital & Medical Center
  • Cardinal Glennon Children's Hospital
  • VT Children's at Fletcher-Allen Health Care

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Probiotic supplementation

Routine feedings

Arm Description

500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)

Outcomes

Primary Outcome Measures

Growth
Percentage of infants with weight less than the 10th percentile at 34 weeks postmenstrual age.
Growth
Average weight gain and growth velocity during the first 28 days from initiation of feeding.
Feeding Tolerance
Volume of feeding per day during the first 28 days from the initiation of feeding.

Secondary Outcome Measures

Antimicrobial therapy
Days of antimicrobial treatment until 34 weeks post menstrual age.
Complications of prematurity
common complications of prematurity including but not limited to sepsis, necrotizing enterocolitis, and mortality.

Full Information

First Posted
July 14, 2010
Last Updated
June 28, 2018
Sponsor
Vermont Oxford Network
Collaborators
University of Vermont, St. Louis University, Cardinal Glennon Children's Hospital, Saint John Hospital & Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01164124
Brief Title
Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants
Acronym
PAS
Official Title
Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
February 2008 (undefined)
Primary Completion Date
May 2009 (Actual)
Study Completion Date
August 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vermont Oxford Network
Collaborators
University of Vermont, St. Louis University, Cardinal Glennon Children's Hospital, Saint John Hospital & Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The overall purpose of this research is to test whether adding a supplement to the feeding of extremely low birth weight infant (infants weighing less than 2 pound 2 oz at birth) will help him/her achieve full feeding faster and achieve better weight gain.
Detailed Description
The overall purpose of this research is to test whether adding a supplement to the feeding of extremely low birth weight infant (infants weighing less than 2 pound 2 oz at birth) will help him/her achieve full feeding faster and achieve better weight gain. The study also will evaluate the benefit of that feeding supplement in decreasing the rate of infection (in the blood or in the urine) and antibiotics use in those infants. When babies are born, the digestive system (the gastrointestinal tract) is sterile. There are no bacteria residing in their gut. When babies start feeding, it is normal for the intestine to start growing several types of bacteria. These normal (good) bacteria are thought to be helpful in keeping the intestine healthy. This is not the case in premature infants. It takes premature infants a longer time to grow bacteria in their intestines and they have fewer numbers of bacteria. In addition, the bacteria premature infants grow are not the normal one that we see in healthy infants. Instead they grow unhealthy (bad) bacteria that can potentially play a role in causing infection in the blood and urine. Adding the normal (good) bacteria to the breast milk or infant formula might help to protect premature babies from developing blood or urine infection. In addition, adding the good bacteria might be beneficial in terms of better tolerance to milk feeding. As a result, babies may have less episodes of feeding holding and have better weight gain. Two species of bacteria, called Lactobacillus and Bifidobacteria, have been used to study this in other studies of premature babies. These two species are the most plentiful bacteria seen in the bowels of full term babies. Participation in the study involves enrolling premature babies to receive supplement to the feeding when he/she ready to feed. Babies will be randomly assigned to receive either a bacteria (probiotic) supplement or be fed without supplement. The supplement will be added to one feeding each day. Enrolled babies will continue to get the supplement for 6-10 week. Other than the feeding supplement, being in this study will not affect care. The main outcomes of the study will be feeding tolerance and growth. Other complications associated with prematurity, on particular infection of either the gastrointestinal tract or the blood stream will be evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Birth Weight
Keywords
extremely low birth weight, probiotics, growth, nutrition, premature infants, growth in extremely low birth weight infants

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
101 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Probiotic supplementation
Arm Type
Experimental
Arm Description
500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
Arm Title
Routine feedings
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)
Intervention Description
The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
routine feedings
Primary Outcome Measure Information:
Title
Growth
Description
Percentage of infants with weight less than the 10th percentile at 34 weeks postmenstrual age.
Time Frame
34 weeks postmenstrual age
Title
Growth
Description
Average weight gain and growth velocity during the first 28 days from initiation of feeding.
Time Frame
28 days from study entry
Title
Feeding Tolerance
Description
Volume of feeding per day during the first 28 days from the initiation of feeding.
Time Frame
28 days from study entry
Secondary Outcome Measure Information:
Title
Antimicrobial therapy
Description
Days of antimicrobial treatment until 34 weeks post menstrual age.
Time Frame
34 weeks post menstrual age
Title
Complications of prematurity
Description
common complications of prematurity including but not limited to sepsis, necrotizing enterocolitis, and mortality.
Time Frame
until hospital discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
14 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: birth weight less than or equal to 1000 grams, appropriately grown for gestational age, age 1 to 14 days inclusive, intention to start enteral feeds, written informed consent obtained Exclusion Criteria: known life-threatening congenital anomaly or condition affecting gastrointestinal function, previous NEC or gastrointestinal perforation, previous supplementation with probiotics previous enteral feedings
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohamad Al-Hosni, MD
Organizational Affiliation
St. Louis University
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. John Hospital & Medical Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48236
Country
United States
Facility Name
Cardinal Glennon Children's Hospital
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63104-1095
Country
United States
Facility Name
VT Children's at Fletcher-Allen Health Care
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants

We'll reach out to this number within 24 hrs